Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. World Health Organization. International Classification of Diseases for Mortality and Morbidity Statistics (11th Revision). Available at https://icd.who.int/browse/2025-01/mms/en. Last accessed September 10, 2026.
2. Fryar CD, Carroll MD, Afful J. Prevalence of Overweight, Obesity, and Severe Obesity Among Adults Aged 20 and Over: United States, 1960–1962 through 2017–2018. Hyattsville, MD: National Center for Health Statistics; 2020.
3. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023. NCHS Data Brief. 2024;(508).
4. Angelidi AM, Belanger MJ, Kokkinos A, et al. Novel noninvasive approaches to the treatment of obesity: from pharmacotherapy to gene therapy. Endocr Rev. 2022;43(3):507-557.
5. O'Hara VM, Curran JL, Browne NT. The co-occurrence of pediatric obesity and ADHD: an understanding of shared pathophysiology and implications for collaborative management. Curr Obes Rep. 2020;9(4):451-461.
6. Lister NB, Baur LA, Felix JF, et al. Child and adolescent obesity. Nat Rev Dis Primers. 2023;9:24.
7. Fitch AK, Malhotra S, Conroy R. Differentiating monogenic and syndromic obesities from polygenic obesity: assessment, diagnosis, and management. Obesity Pillars. 2024;11:100110.
8. Heindel JJ, Lustig RH, Howard S, et al. Obesogens: a unifying theory for the global rise in obesity. Int J Obes (Lond). 2024;48:449-460.
9. Lustig RH, Collier D, Kassotis C, et al. Obesity I: overview and molecular and biochemical mechanisms. Biochem Pharmacol. 2022;199:115012.
10. Caprio S, Santoro N, Weiss R. Childhood obesity and the associated rise in cardiometabolic complications. Nat Metab. 2020;2(3):223-232.
11. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.
12. Salimi-Jazi F, Chkhikvadze T, Shi J, et al. Trends in adolescent bariatric procedures: a 15-year analysis of the National Inpatient Survey. Obes Surg. 2022;32(11):3658-3665.
13. Olbers T, Beamish AJ, Gronowitz E, et al. Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study. Lancet Diabetes Endocrinol. 2017;5:174-183.
14. Kohut T, Robbins J, Panganiban J. Update on childhood/adolescent obesity and its sequela. Curr Opin Pediatr. 2019;31:645-653.
15. Cuda S; Obesity Medicine Association. Special considerations for the adolescent with obesity: an Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024. Obesity Pillars. 2024;9:100096.
16. Cuda S, Censani M, Kharofa R, et al. Medication-induced weight gain and advanced therapies for the child with overweight and obesity: an Obesity Medicine Association (OMA) clinical practice statement 2022. Obesity Pillars. 2022;4:100048.
17. Fox C, O'Hara V. Understanding obesity and setting the stage for comprehensive treatment. In: Fox C (ed). Managing Pediatric Obesity Using Advanced Therapies: Practical Guide for Pediatric Health Care Providers. New York, NY: Springer; 2022.
18. Hegedus E, Vidmar AP, Mayer M, et al. Approach to the treatment of children and adolescents with obesity. Gastrointest Endoscopy Clin N Am. 2024;34:781-804.
19. O'Hara V, Cuda S, Kharofa R, et al. Clinical review: guide to pharmacological management in pediatric obesity medicine. Obesity Pillars. 2023;6:100066.
20. Pratt JSA, et al. ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis. 2018;14:882-901.
21. Kelly AS, Marcus MD, Yanovski JA, et al. Working toward precision medicine approaches to treat severe obesity in adolescents: report of an NIH workshop. Int J Obes (Lond). 2018;42:1834-1844.
22. Ogle SB, Dewberry LC, Jenkins TM, et al. Outcomes of bariatric surgery in older versus younger adolescents. Pediatrics. 2021;147(3): e2020024182.
23. Inge TH, Jenkins TM, Xanthakos SA, et al. Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis. Lancet Diabetes Endocrinol. 2017;5(3):165-173.
24. Ryder JR, Gross AC, Fox CK, et al. Factors associated with long-term weight-loss maintenance following bariatric surgery in adolescents with severe obesity. Int J Obes (Lond). 2018;42(1):102-107.
25. de la Cruz-Munoz N, Xie L, Quiroz HJ, et al. Long-term outcomes after adolescent bariatric surgery. J Am Coll Surg. 2022;235:592-602.
26. Alqahtani AR, Elahmedi M, Abdurabu HY, et al. Ten-year outcomes of children and adolescents who underwent sleeve gastrectomy: weight loss, comorbidity resolution, adverse events, and growth velocity. J Am Coll Surg. 2021;233(6):657-664.
27. Cuda S, Censani M. Progress in pediatric obesity: new and advanced therapies. Curr Opin Pediatr. 2022;34:407-413.
28. Sweeney B, Kelly AS, San Giovanni CB, et al. Clinical approaches to minimize iatrogenic weight gain in children and adolescents. Clin Obes. 2020;e12417.
29. Skelton JA, Klish WJ. Definition, Epidemiology, and Etiology of Obesity in Children and Adolescents. Treasure Island, FL: UpToDate; 2023.
30. Skinner AC, Staiano AE, Armstrong SC, et al. Appraisal of clinical care practices for child obesity treatment. Part I: interventions. Pediatrics. 2023;151(2):e2022060642.
31. Cuda SE, Censani M. Assessment, differential diagnosis, and initial clinical evaluation of the pediatric patient with obesity: an Obesity Medical Association (OMA) clinical practice statement 2022. Obesity Pillars. 2022;1:100010.
32. Freedman DS, Butte NF, Taveras EM, et al. The limitations of transforming very high body mass indexes into z-scores among 8.7 million 2- to 4-year-old children. J Pediatr. 2017;188:50-56.e51.
33. Fryar CD, Carroll MD, Afful J. Prevalence of Overweight, Obesity, and Severe Obesity Among Children and Adolescents Aged 2–19 Years: United States, 1963–1965 through 2017–2018. Hyattsville, MD: National Center for Health Statistics; 2020.
34. QuickStats: prevalence of obesity and severe obesity among persons aged 2–19 years—United States, 1999–2000 through 2021–2023. MMWR. 2024;73:936.
35. Zhao L, Freedman DS, Blanck HM, Park S. Trends in severe obesity among children aged 2 to 4 years in WIC: 2010 to 2020. Pediatrics. 2024;153(1):e2023062461.
36. Ferentinou E, Koutelekos I, Pappa D, Manthou P, Dafogianni C. The impact of the COVID-19 pandemic on childhood obesity: a review. Cureus. 2023;15(9):e45470.
37. Centers for Disease Control and Prevention. Childhood Obesity Facts: Overweight and Obesity. Available at https://www.cdc.gov/obesity/childhood-obesity-facts/childhood-obesity-facts.html. Last accessed September 18, 2026.
38. Bouchard C. Genetics of obesity: what we have learned over decades of research. Obesity. 2021;29:802-820.
39. Lazarus E, Ortiz-Pujols S. Increasing clinical awareness of obesity as a serious, chronic, relapsing, and treatable disease. Am J Manag Care. 2022;28:S271-S278.
40. Aagaard KM, Barkin SL, Burant CF, et al. Understanding risk and causal mechanisms for developing obesity in infants and young children: a National Institutes of Health workshop. Obes Rev. 2024;e13690.
41. Hinney A, Peters T, Rajcsanyi LS. Benign form of monogenic obesity conferred by the melanocortin 4 receptor. Cell Metab. 2026;38(1):12-13.
42. Amato AA, Wheeler HB, Blumberg B. Obesity and endocrine-disrupting chemicals. Endocr Connect. 2021;10:R87-R105.
43. Shan Z, Rehm CD, Rogers G, et al. Trends in dietary carbohydrate, protein, and fat intake and diet quality among US adults, 1999–2016. JAMA. 2019;322:1178-1187.
44. Brown RE, Sharma AM, Ardern CI, et al. Secular differences in the association between caloric intake, macronutrient intake, and physical activity with obesity. Obes Res Clin Pract. 2016;10:243-255.
45. International Atomic Energy Agency. Obesity Crisis: New IAEA Database to Help Countries Tackle Growing Obesity Crisis. Available at https://www.iaea.org/newscenter/news/obesity-crisis-new-iaea-database-to-help-countries-tackle-nutrition-challenges. Last accessed September 18, 2026.
46. Speakman JR, et al. The IAEA international doubly-labelled water database: aims, scope and procedures. Ann Nutr Metab. 2019;75:114-118.
47. Speakman JR, de Jong JMA, Sinha S, et al. Total daily energy expenditure has declined over the past three decades due to declining basal expenditure, not reduced activity expenditure. Nat Metab. 2023;5(4):579-588.
48. Corkey BE. Reactive oxygen species: role in obesity and mitochondrial energy efficiency. Philos Trans R Soc Lond B Biol Sci. 2023;378(1885):20220210.
49. Heindel JJ, Alvarez JA, Atlas E, et al. Obesogens and obesity: state-of-the-science and future directions summary from a Healthy Environment and Endocrine Disruptors Strategies workshop. Am J Clin Nutr. 2023;118:329-337.
50. Heindel JJ, Howard S, Agay-Shay K, et al. Obesity II: establishing causal links between chemical exposures and obesity. Biochem Pharmacol. 2022;199:115015.
51. Nigg JT. Annual research review: on the relations among self-regulation, self-control, executive functioning, effortful control, cognitive control, impulsivity, risk-taking, and inhibition for developmental psychopathology. J Child Psychol Psychiatry. 2017;58(4):361-383.
52. Dellenmark-Blom M, Järvholm K, Sjögren L, et al. Neurodevelopmental disorders in children seeking obesity treatment—associations with intellectual ability and psychiatric conditions. Front Psychiatry. 2024;15:1332598.
53. Vourdoumpa A, Paltoglou G, Charmandari E. The genetic basis of childhood obesity: a systematic review. Nutrients. 2023;15:1416.
54. Fox CK, Gross AC, Bomberg EM, et al. Severe obesity in the pediatric population: current concepts in clinical care. Curr Obes Rep. 2019;8:201-209.
55. Concepción-Zavaleta MJ, Quiroz-Aldave JE, Durand-Vásquez MDC, et al. A comprehensive review of genetic causes of obesity. World J Pediatr. 2024;20(1):26-39.
56. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120-133.
57. Dubern B, Faccioli N, Poitou C, et al. Novel therapeutics in rare genetic obesities: a narrative review. Pharmacol Res. 2023;191:106763.
58. Faccioli N, Poitou C, Clément K, et al. Current treatments for patients with genetic obesity. J Clin Res Pediatr Endocrinol. 2023;15(2): 108-119.
59. Roh E, Kim MS. Brain regulation of energy metabolism. Endocrinol Metab (Seoul). 2016;31(4):519-524.
60. Sićović K, Micov A. Pharmacotherapy of obesity: state of the art and perspectives. Arh Farm. 2024;74:460-482.
61. Affinati AH, Myers MG Jr. Neuroendocrine control of body energy homeostasis. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. MDText.com; 2021.
62. Watts AG, Kanoski SE, Sanchez-Watts G, et al. The physiological control of eating: signals, neurons, and networks. Physiol Rev. 2022;102:689-813.
63. Westerterp KR. Control of energy expenditure in humans. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. MDText.com; 2021.
64. Liu CM, Kanoski SE. Homeostatic and non-homeostatic controls of feeding behavior: distinct vs. common neural systems. Physiol Behav. 2018;193(Pt B):223-231.
65. Pucci A, Batterham RL. Endocrinology of the gut and the regulation of body weight and metabolism. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. MDText.com; 2021.
66. Feingold KR. Role of glucose and lipids in the atherosclerotic cardiovascular disease of patients with diabetes. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. MDText.com; 2021.
67. Brondeel KC, Lakatta AC, Torres GB, et al. Physiologic and pharmacologic considerations in morbid obesity and bariatric anesthesia. Saudi J Anaesth. 2022;16:306-313.
68. Hollstein T, Piaggi P. Metabolic factors determining the susceptibility to weight gain: current evidence. Curr Obes Rep. 2020;9:121-135.
69. Savova MS, Mihaylova LV, Tews D, et al. Targeting PI3K/AKT signaling pathway in obesity. Biomed Pharmacother. 2023;159:114244.
70. Richard AJ, White U, Elks CM, et al. Adipose tissue: physiology to metabolic dysfunction. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. MDText.com; 2021.
71. Heindel JJ, Blumberg B, Cave M, et al. Metabolism disrupting chemicals and metabolic disorders. Reprod Toxicol. 2017;68:3-33.
72. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7:95-96.
73. Attia P. Narrative Glossary. Available at https://peterattiamd.com/narrative-glossary. Last accessed September 18, 2026.
74. Bays HE, Bindlish S, Clayton TL. Obesity, diabetes mellitus, and cardiometabolic risk: an Obesity Medicine Association (OMA) clinical practice statement (CPS) 2023. Obesity Pillars. 2023;5:100056.
75. Keshavjee SH, Schwenger KJP, Yadav J, et al. Factors affecting metabolic outcomes post bariatric surgery: role of adipose tissue. J Clin Med. 2021;10:714.
76. Kirichenko TV, Markina YV, Bogatyreva AI, et al. The role of adipokines in inflammatory mechanisms of obesity. Int J Mol Sci. 2022;23:14982.
77. Askarpour M, Alizadeh S, Hadi A, et al. Effect of bariatric surgery on the circulating level of adiponectin, chemerin, plasminogen activator inhibitor-1, leptin, resistin, and visfatin: a systematic review and meta-analysis. Horm Metab Res. 2020;52:207-215.
78. Khanna D, Welch BS, Rehman A. Pathophysiology of obesity. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2025.
79. Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017;10:223-234.
80. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375-C391.
81. Marcus C, Danielsson P, Hagman E. Pediatric obesity—long-term consequences and effect of weight loss. J Intern Med. 2022;292:870-891.
82. Kavey RW. Combined dyslipidemia in children and adolescents. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. MDText.com; 2023.
83. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014;63:250-259.
84. Jin X, Qiu T, Li L, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B. 2023;13(6):2403-2424.
85. Perdomo CM, Avilés-Olmos I, Dicker D, Frühbeck G. Towards an adiposity-related disease framework for the diagnosis and management of obesities. Rev Endocr Metab Disord. 2023;24(5):795-807.
86. Freeman AM, Acevedo LA, Pennings N. Insulin resistance. In: StatPearls. Tredasure Island, FL: StatPearls Publishing; 2025.
87. Montégut L, Lopez-Otin C, Magnan C, et al. Old paradoxes and new opportunities for appetite control in obesity. Trends Endocrinol Metab. 2021;32(5):264-294.
88. Balasundaram P, Krishna S. Obesity effects on child health. In: StatPearls. Tredasure Island, FL: StatPearls Publishing; 2023.
89. Skelton JA, Klish WJ. Overview of the Health Consequences of Obesity in Children and Adolescents. Available at https://www.uptodate.com/contents/overview-of-the-health-consequences-of-obesity-in-children-and-adolescents. Last accessed September 18, 2026.
90. Cioana M, Deng J, Nadarajah A, et al. The prevalence of obesity among children with type 2 diabetes: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(12):e2247186.
91. Price J, Urbina EM, Carlin K, et al. Cardiovascular risk factors and target organ damage in adolescents: the SHIP AHOY Study. Pediatrics. 2022;149(6):e2021054201.
92. Valerio M, Di Bonito P, Calcaterra V, et al. Cardiometabolic risk in children and adolescents with obesity: a position paper of the Italian Society for Pediatric Endocrinology and Diabetology. Ital J Pediatr. 2024;50:205.
93. Yu EL, Golshan S, Harlow KE, et al. Prevalence of nonalcoholic fatty liver disease in children with obesity. J Pediatr. 2019;207:64-70.
94. AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev. 2015;16:393-405.
95. Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:1-22.
96. Panganiban J, Kehar M, Ibrahim SH, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025. Obes Pillars. 2025;14:100164.
97. Barlabà A, Grella C, Tammaro M, et al. Kidney function evaluation in children and adolescents with obesity: a not-negligible need. Eur J Pediatr. 2024;183(9):3655-3664.
98. Du Y, Curtis A, Lalonde A, et al. The effect of weight loss interventions on free androgen index in women with PCOS: a meta-regression. Obesity (Silver Spring). 2023;31(suppl 2):53-289.
99. Chhabria SM, LeBron J, Ronis SD, et al. Diagnosis and management of hypertension in adolescents with obesity. Curr Cardiovasc Risk Rep. 2024;18:115-124.
100. Tung JYL, Poon GWK, Du J, Wong KKY. Obesity in children and adolescents: overview of the diagnosis and management. Chronic Dis Transl Med. 2023;9:122-133.
101. Vandana P, Veenstra-VanderWeele J. Failing in our responsibility to address obesity caused by psychotropic medications [editorial]. J Am Acad Child Adolesc Psychiatry. 2023;62(11):1194-1196.
102. Vajravelu ME, Tas E, Arslanian S. Pediatric obesity: complications and current day management. Life. 2023;13:1591.
104. Kelly AS, Armstrong SC, Michalsky MP, Fox CK. Obesity in adolescents: a review. JAMA. 2024;332(9):738-748.
105. Torbahn G, Lischka J, Brown T, et al. Anti-obesity medication in the management of children and adolescents with obesity: recent developments and research gaps. Clin Endocrinol (Oxf). 2024:1-11.
106. Patel PN, Fox CK, Bensignor MO, et al. Weight loss from combination anti-obesity medication regimens can approach that achieved from bariatric surgery. JCEM Case Rep. 2023;1:1-4.
107. Srivastava G, Fox CK, Kelly AS, et al. Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity. Obesity. 2019;27(2):190-204.
108. Mozaffarian D. Perspective: obesity: an unexplained epidemic. Am J Clin Nutr. 2022;115:1445-1450.
109. Brown TJ, Mead E, Ells LJ. Behavior-Changing Interventions for Treating Overweight or Obesity in Children Aged 6 to 11 Years. JAMA Pediatr. 2019;173(4):385-386.
110. U.S. Preventive Services Task Force. Interventions for high body mass index in children and adolescents: U.S. Preventive Services Task Force Recommendation Statement. JAMA. 2024;332(3):226-232.
111. Menzin ER. Mission impossible? Managing the American Academy of Pediatrics' obesity guideline. Ann Fam Med. 2024;22:170-171.
112. Ruiz-Cota P, Bacardí-Gascón M, Jiménez-Cruz A. Long-term outcomes of metabolic and bariatric surgery in adolescents with severe obesity with a follow-up of at least 5 years: a systematic review. Surg Obes Relat Dis. 2019;15(1):133-144.
113. Eisenberg D, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. Obes Surg. 2023;33:3-14.
114. Salminen P, Kow L, Aminian A, et al. IFSO consensus on definitions and clinical practice guidelines for obesity management: an international Delphi study. Obes Surg. 2024;34:30-42.
115. Kermansaravi M, Chiappetta S, Parmar C, et al. Current recommendations for procedure selection in class I and II obesity developed by an expert modified Delphi consensus. Sci Rep. 2024;14:3445.
116. Malhotra S, Czepiel KS, Akam EY, et al. Bariatric surgery in the treatment of adolescent obesity: current perspectives in the United States. Expert Rev Endocrinol Metab. 2021;16:123-134.
117. Fleming MA 2nd, Jenkins TM, Inge TH, et al. Weight loss and health status 10 years after laparoscopic adjustable gastric band insertion in adolescents: a follow-up report from Teen-LABS. Surg Obes Relat Dis. 2025;21(1):33-40.
118. Dewberry LC, Jalivand A, Gupta R, et al. Weight loss and health status 5 years after adjustable gastric banding in adolescents. Obes Surg. 2020;30(6):2388-2394.
119. Inge TH, Courcoulas AP, Jenkins TM, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374(2):113-123.
120. Xanthakos S, Khoury JC, Inge TH, et al. Nutritional risks in adolescents after bariatric surgery. Clin Gastroenterol Hepatol. 2020;18(5): 1070-1081.
121. Inge TH, Courcoulas AP, Jenkins TM, et al. Five-year outcomes of gastric bypass in adolescents as compared with adults. N Engl J Med. 2019;380(22):2136-2145.
122. Järvholm K, Janson A, Peltonen M, et al. Metabolic and bariatric surgery versus intensive non-surgical treatment for adolescents with severe obesity (AMOS2): a multicentre, randomised, controlled trial in Sweden. Lancet Child Adolesc Health. 2023;7:249-260.
123. Inge TH, Coley RY, Bazzano LA, et al. Comparative effectiveness of bariatric procedures among adolescents: the PCORnet bariatric study. Surg Obes Relat Dis. 2018;14(9):1374-1386.
124. Alqahtani A, Elahmedi M, Qahtani AR. Laparoscopic sleeve gastrectomy in children younger than 14 years: refuting the concerns. Ann Surg. 2016;263(2):312-319.
125. Shah A, Liang NE, Bruzoni M, et al. Outcomes after metabolic and bariatric surgery in preteens versus teens using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program database and center-specific data. Obesity (Silver Spring). 2024;32(1):150-155.
126. Liang NE, Herdes RE, Balili R, et al. Sleeve gastrectomy for the treatment of adolescent obesity in children aged 13 and under: a retrospective study. Surg Obes Relat Dis. 2024;20:354-361.
127. Cheng V, Grinberg GG, Ashbrook M, et al. Predictors of complications following bariatric surgery for adolescent patients. Am Surg. 2023;89(10):4031-4037.
128. Kim A, Nguyen J, Babaei M, et al. A narrative review: phentermine and topiramate for the treatment of pediatric obesity. Adolesc Health Med Ther. 2023;14:125-140.
129. Fox C. Anti-Obesity Medication Protocols. Available at https://pedsendo.org/wp-content/uploads/2024/06/170571_1.11.24-PedsMetaObesity_Anti_Obesity_Medications_Providers_Toolkit_Booklet_v1.pdf. Last accessed September 18, 2026.
130. Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387:2245-2257.
131. Welling MS, de Groot CJ, Mohseni M, et al. Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study. EClinicalMedicine. 2024;74:102709.
132. Kleinendorst L, Massink MPG, Cooiman MI, et al. Genetic obesity: next-generation sequencing results of 1230 patients with obesity.J Med Genet. 2018;55(9):578-586.
133. Welling MS, de Groot CJ, Kleinendorst L, et al. Effects of glucagon-like peptide-1 analogue treatment in genetic obesity: a case series. Clin Obes. 2021;11(6):e12481.
134. Rhythm Pharmaceuticals. IMCIVREE (setmelanotide) [prescribing information]. Rhythm Pharmaceuticals; 2023.
135. Roth CL, Scimia C, Shoemaker AH, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024;12(6):380-389.
136. Amryt Pharmaceuticals. MYALEPT (metreleptin) [prescribing information]. Amryt Pharmaceuticals; 2022.
137. Mainieri F, La Bella S, Rinaldi M, Chiarelli F. Rare genetic forms of obesity in childhood and adolescence: a narrative review of the main treatment options with a focus on innovative pharmacological therapies. Eur J Pediatr. 2024;183(4):1499-1508.
138. Diene G, Angulo M, Hale PM, et al. Liraglutide for weight management in children and adolescents with Prader-Willi syndrome and obesity. J Clin Endocrinol Metab. 2022;108:4-12.
139. Katole NT, Salankar HV, Khade AM, et al. The antiobesity effect and safety of GLP-1 receptor agonist in overweight/obese adolescents without diabetes mellitus: a systematic review and meta-analysis. Cureus. 2024;16(8):e66280.
140. Raman V, Gupta A, Ashraf AP, et al. Pharmacologic weight management in the era of adolescent obesity. J Clin Endocrinol Metab. 2022;107:2716-2728.
141. The Medical Letter. Tirzepatide (Zepbound) for chronic weight management. Med Lett Drugs Ther. 2023;65:205-207.
142. Jung HW. Current options in obesity pharmacotherapy for children and adolescents. Precis Future Med. 2024;8(2):38-49.
143. Son JE. Genetics, pharmacotherapy, and dietary interventions in childhood obesity. J Pharm Pharm Sci. 2024;27:12861.
144. Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025;77(1):100002.
145. Liu L, Shi H, Shi Y, et al. Comparative efficacy and safety of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity or overweight: a systematic review and network meta-analysis. Pharmaceuticals. 2024;17:828.
146. Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873-1888.
147. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526.
148. Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117-2128.
149. Bensignor MO, Kelly AS, Arslanian S. Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: review of the literature and lessons learned from adults. Front Endocrinol (Lausanne). 2022;13:1043650.
150. Fox CK, Barrientos-Pérez M, Bomberg EM, et al. Liraglutide for children 6 to <12 years of age with obesity: a randomized trial. N Engl J Med. 2025;392(6):555-565.
151. Gou H, Zhai Y, Guo J. Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials. Eur J Pediatr. 2023;182(11):5095-5108.
152. Dauleh H, Pasha M, Gad H, et al. Single-center experience of using liraglutide in adolescents with obesity +/- type 2 diabetes. Cureus. 2024;16(4):e58720.
153. Ghusn W, Hurtado MD. Glucagon-like receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obesity Pillars. 2024;12:100127.
154. Kelly AS, Arslanian S, Hesse D, et al. Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg. Obesity (Silver Spring). 2023;31:2139-2149.
155. Coutinho W, Halpern B. Pharmacotherapy for obesity: moving towards efficacy improvement. Diabetol Metab Syndr. 2024;16(1):6.
156. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
157. Fox CK, et al. Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly versus Placebo in Adolescent Participants Who Have Obesity, or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS). Available at https://experts.umn.edu/en/projects/efficacy-safety-and-pharmacokinetics-of-tirzepatide-once-weekly-v-2/fingerprints. Last accessed September 18, 2026.
158. Makunts T, Joulfayan H, Abagyan R. Thyroid hyperplasia and neoplasm adverse events associated with glucagon-like peptide-1 receptor agonists in the Food and Drug Administration Adverse Event Reporting System: retrospective analysis. JMIRx Med. 2024;5:e55976.
159. Hu W, Song R, Cheng R, et al. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:927859.
160. Bezin J, Gouverneur A, Penichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46:384-390.
161. Sherwin M, et al. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide. Can J Anaesth. 2023;70(8):1300-1306.
162. Facciorusso A, Ramai D, Dhar J, et al. Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis. Clin Gastroenterol Hepatol. 2025;23(5):715-725.
163. Kerem L, Stokar J. Risk of suicidal ideation or attempts in adolescents with obesity treated with GLP-1 receptor agonists. JAMA Pediatr. 2024;178(12):1307-1315.
164. Bomberg EM, Clark J, Rudser KD, et al. Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting. Pediatr Obes. 2024;19:e13143.
165. Coulter AA, Rebello CJ, Greenway FL. Centrally acting drugs for obesity: past, present, and future. Drugs. 2018;78:1113-1132.
166. Hsia DS, Gosselin NH, Williams J, et al. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity. Diabetes Obes Metab. 2020;22:480-491.
167. Kelly AS, Bensignor MO, Hsia DS, et al. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1(6).
168. Enright C, Thomas E, Saxon DR. An updated approach to antiobesity pharmacotherapy: moving beyond the 5% weight loss goal.J Endocr Soc. 2023;7:1-12.
169. Yang Q, Wang J, Wang M, et al. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database. BMC Pharmacol Toxicol. 2024;25:64.
170. Jastreboff AM, Kushner RF. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annu Rev Med. 2023;74:125-139.
171. Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293:2873-2883.
172. Chanoine JP, Richard M. Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. Int J Pediatr Obes. 2011;6:95-101.
173. Nikniaz Z, Nikniaz L, Farhangi MA, et al. Effect of orlistat on anthropometrics and metabolic indices in children and adolescents: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23:142.
174. Viner RM, Hsia Y, Neubert A, Wong IC. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. Br J Clin Pharmacol. 2009;68:844-851.
175. Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225.
176. Ahn YJ, Maya J, Singhal V. Update on pediatric anti-obesity medications—current landscape and approach to prescribing. Curr Obes Rep. 2024;13:295-312.
177. Van Norman GA. Off-label use vs off-label marketing of drugs. Part 1: off-label use—patient harms and prescriber responsibilities. JACC Basic Transl Sci. 2023;8:224-233.
178. Cuda S; Obesity Medicine Association. Special considerations for the child with obesity: an Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024. Obesity Pillars. 2024;11:100113.
179. Braüner JV, Johansen LM, Roesbjerg T, et al. Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry.J Clin Psychopharmacol. 2016;36(5):500-507.
180. Hoon D, Taylor MT, Kapadia P, et al. Trends in off-label drug use in ambulatory settings: 2006–2015. Pediatrics. 2019;144(4):e20190896.
181. Frattarelli DA, Galinkin JL, Green TP, et al. Off-label use of drugs in children. Pediatrics. 2014;133:563-567.
182. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002;10:633-641.
183. Brownley KA, Berkman ND, Peat CM, et al. Binge-eating disorder in adults: a systematic review and meta-analysis. Ann Intern Med. 2016;165(6):409-420.
184. Saleh A, Lim R, Khorgami Z, et al. Combined therapy of severe obesity with bariatric surgery, GLP-1 agonist, and genetic-based therapy. Obesity (Silver Spring). 2023;31(suppl 2):283.
185. McCorkle C, Dorand M, Lim R, et al. Setmelanotide and tirzepatide polytherapy for weight management in Bardet-Biedl syndrome. Obesity (Silver Spring). 2023;31(suppl 2):183.
186. Hollander P, Bays HE, Rosenstock J, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40:632-639.
187. Kohut T, Tou A, Carr E, et al. Topiramate treatment of pediatric metabolic dysfunction-associated steatotic liver disease: a descriptive cohort study. JPEN J Parenter Enteral Nutr. 2025;49(3):308-313.
188. Heal DJ, Gosden J, Smith SL. Stimulant prodrugs: a pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder. Adv Pharmacol. 2024;99:251-286.
189. Cortese S, Moreira-Maia CR, St Fleur D, et al. Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(1):34-43.
190. Reed C, Cortese S, Golm D, Brandt V. Longitudinal associations between attention-deficit/hyperactivity and weight from birth to adolescence. J Am Acad Child Adolesc Psychiatry. 2025;64(10):1192-1200.
191. Racicka-Pawlukiewicz E, Hanć T, Kuć K, et al. The occurrence of overweight and obesity in children and adolescents with attention-deficit/hyperactivity disorder according to three different diagnostic criteria for obesity. J Child Adolesc Psychopharmacol. 2021;31(6):430-438.
192. Heal DJ, Smith SL. Prospects for new drugs to treat binge-eating disorder: insights from psychopathology and neuropharmacology.J Psychopharmacol. 2022;36(6):680-703.
193. Caci H, Chierici A, Iannelli A. Attention-deficit/hyperactivity disorder in adolescent and adult candidates for metabolic and bariatric surgery: a systematic review and meta-analysis. Obes Rev. 2024;e13802.
194. Ramalho SM, Conceição E, Tavares AC, et al. Loss of control over eating, inhibitory control, and reward sensitivity in children and adolescents: a systematic review. Nutrients. 2023;15:2673.
195. Keshen AR, Hilbert A, Taylor V, et al. Effect of stimulant medication on loss of control eating in youth with attention deficit/hyperactivity disorder: a prospective, observational case series study protocol. J Eat Disord. 2022;10:152.
196. Namimi-Halevi C, Dor C, Stark AH, et al. Attention-deficit hyperactivity disorder is associated with disordered eating in adolescents. Pediatr Res. 2024;96(4):1068-1075.
197. Kase BE, Rommelse N, Chen Q, et al. Longitudinal associations between symptoms of ADHD and BMI from late childhood to early adulthood. Pediatrics. 2021;147(6):e2020036657.
198. Fuemmeler BF, Sheng Y, Schechter JC, et al. Associations between attention deficit hyperactivity disorder symptoms and eating behaviors in early childhood. Pediatr Obes. 2020;15(7):e12631.
199. Likhitweerawong N, Louthrenoo O, Boonchooduang N, et al. Bidirectional prediction between weight status and executive function in children and adolescents: a systematic review and meta-analysis of longitudinal studies. Obes Rev. 2022;23:e13458.
200. AlAhmari F, Uddin M. Prevalence of obesity in treated and untreated patients with attention deficit hyperactivity disorder. Saudi Med J. 2022;43:873-880.
201. Byrd HC, Curtin C, Anderson SE. Attention-deficit/hyperactivity disorder and obesity in US males and females, age 8–15 years: National Health and Nutrition Examination Survey 2001–2004. Pediatr Obes. 2013;8(6):445-453.
202. Levy LD, Fleming JP, Klar D. Treatment of refractory obesity in severely obese adults following management of newly diagnosed attention deficit hyperactivity disorder. Int J Obes (Lond). 2009;33:326-334.
203. Fast K, Björk A, Strandberg M, et al. Half of the children with overweight or obesity and attention-deficit/hyperactivity disorder reach normal weight with stimulants. Acta Paediatr. 2021;00:1-8.
204. Granato MF, Ferraro AA, Lellis DM, et al. Associations between attention-deficit hyperactivity disorder (ADHD) treatment and patient nutritional status and height. Behav Neurol. 2018;2018:7341529.
205. Heal DJ, Gosden J. What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials. Int J Obes (Lond). 2022;46(4):677-695.
206. Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19:214-232.
208. Chen H, Lyu N, Chan W, et al. Utilization and predictors of adjuvant metformin for children and adolescents on mixed receptor antagonists (second-generation antipsychotics). J Am Acad Child Adolesc Psychiatry. 2023;62(11):1245-1255.
209. Correll CU, Cortese S, Croatto G, et al. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. 2021;20:244-275.
210. Cortese S, McGinn K, Højlund M, et al. The future of child and adolescent clinical psychopharmacology: a systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications. Neurosci Biobehav Rev. 2023;149:105149.
211. Klepper C, Crimmins NA, Orkin S, et al. Nonalcoholic fatty liver disease in young children with obesity. Child Obes. 2023;19:179-185.
212. Haemer M, Cluett S, Hassink SG, et al. Building capacity for childhood obesity prevention and treatment in the medical community: call to action. Pediatrics. 2011;128(suppl 2):S71-S77.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.